News
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9 Apr. 14, 2025 7:00 AM ET Verve ...
“These initial Heart-2 data are promising with respect to both safety and efficacy and suggest the potential for a new era of cardiovascular disease treatment where a single dose might lead to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback